Skip to main content
    I

    Invivyd Inc. (IVVD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.67
    +0.06 (+10.04%)

    Market Cap: $179.15M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(10/22)
    Avg Surprise
    -84.47%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.13-15.4%
    60d ago$-0.13-15.4%
    30d ago$-0.150.0%
    7d ago$-0.150.0%
    Current$-0.15
    Revenue Consensus
    $15M
    Range$15M - $16M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.20 - $-0.20
    1 analysts
    Revenue Consensus
    $13M
    Range$10M - $18M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.20---
    Sep 26EST
    		-$-0.15---
    Jun 26
    Reported Aug 13
    		$-0.14$-0.15+6.67%Beat-16.7%
    Mar 26
    Reported May 14
    		$-0.13$-0.08-62.50%Miss+7.1%
    Dec 25
    Reported Mar 5
    		$-0.04N/A+54.51%Beat+73.8%
    Sep 25
    Reported Nov 6
    		$-0.06$-0.09+33.33%Beat+88.2%
    Jun 25
    Reported Aug 14
    		$-0.12$0.01-1300.00%Miss+70.0%
    Mar 25
    Reported May 15
    		$-0.14$-0.04-250.00%Miss+63.2%
    Dec 24
    Reported Mar 20
    		$-0.15$-0.10-50.00%Miss+77.6%
    Sep 24
    Reported Nov 14
    		$-0.51$-0.35-45.71%Miss-41.7%
    Jun 24
    Reported Aug 14
    		$-0.40$-0.39-2.56%Miss+13.0%
    Mar 24
    Reported May 9
    		$-0.38$-0.39+2.56%Beat-18.8%
    Dec 23
    Reported Mar 28
    		$-0.67$-0.42-59.52%Miss-168.0%
    Sep 23
    Reported Nov 9
    		$-0.36$-0.50+28.00%Beat+14.3%
    Jun 23
    Reported Aug 10
    		$-0.46$-0.45-2.22%Miss+2.1%
    Mar 23
    Reported May 11
    		$-0.32$-0.48+33.33%Beat+64.8%
    Dec 22
    Reported Mar 23
    		$-0.25$-0.39+35.90%Beat+67.5%
    Sep 22
    Reported Nov 10
    		$-0.42$-0.37-13.51%Miss+52.8%
    Jun 22
    Reported Aug 15
    		$-0.47$-0.50+6.00%Beat-161.1%
    Mar 22
    Reported May 13
    		$-0.91$-0.56-62.50%Miss+57.5%
    Dec 21
    Reported Mar 30
    		$-0.77$-1.03+25.24%Beat-
    Sep 21
    Reported Nov 15
    		$-0.89$-0.57-56.14%Miss-
    Jun 21
    Reported Aug 6
    		$-0.18N/A+77.50%Beat-
    Mar 21
    Reported Jun 2
    		$-2.14$-0.60-256.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio-1.81EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-183.90%Operating Margin-320.80%
    ROE-95.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio5.87xQuick Ratio5.87x
    Trading Statistics
    Beta0.95Avg Volume7.53M
    52-Week High$3.0752-Week Low$0.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.72
    SMA 20$0.81
    SMA 50$0.82
    SMA 200$1.27
    EMA 10$0.71
    EMA 20$0.76
    EMA 50$0.81
    EMA 200$1.08

    MACD

    Line: -0.05Signal: -0.03Hist: -0.02

    ADX

    ADX: 18.0+DI: 20.1-DI: 31.0

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down96.0
    PSAR$0.88

    Bollinger Bands

    Upper Band$1.05
    Lower Band$0.57
    %B Position5867%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    40.0

    Momentum Oscillators

    Stoch %K6.7
    Stoch %D5.1
    Williams %R-83.4
    ROC (10d)-18.1%
    Momentum-0.15
    CCI (20d)-110.1
    MFI (14d)29.7

    Volatility Measures

    ATR (14d)$0.07(11.1%)
    StdDev (20d)0.12
    Hist Vol153.4%(High)

    Volume Flow

    VWAP$0.65
    OBV348.8M
    AD Line-89.2M
    CMF (20d)-0.078

    Volume Metrics

    Avg Vol (20d)7.8M
    Vol Ratio0.4x(Low)
    VWMA (20d)$0.84

    Pivot Points

    R3$0.67
    R2$0.66
    R1$0.63
    Pivot Point$0.62
    S1$0.59
    S2$0.58
    S3$0.55

    Advanced Oscillators

    TSI-16.68
    Ultimate Osc38.2
    KST-123.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$14.29M$13.74M$17.21M$13.13M$11.79M$11.30M$13.82M$9.30M$2.26M$0$3.02M$0
    Cost of Revenue$1.27M$1.03M$1.14M$1.09M$685,000$834,000$724,000$806,000$88,000$0$516,000$0
    Gross Profit$13.01M$12.71M$16.07M$12.04M$11.10M$10.47M$13.10M$8.49M$2.18M$0$2.51M$0
    Operating Expenses$58.83M$55.85M$28.62M$23.06M$26.16M$27.39M$32.33M$70.81M$51.42M$46.09M$76.75M$43.06M
    R&D$29.37M$30.73M$10.05M$8.05M$9.57M$10.64M$17.91M$57.85M$30.33M$31.16M$61.66M$30.17M
    SG&A$29.46M$25.12M$18.57M$15.02M$16.59M$16.75M$14.41M$12.96M$21.09M$14.93M$15.09M$12.89M
    Operating Income$-45,820,000$-43,136,000$-12,555,000$-11,023,000$-15,060,000$-16,922,000$-19,229,000$-62,311,000$-49,247,000$-46,089,000$-76,752,000$-43,060,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-44,393,000$-41,400,000$-11,070,000$-10,470,000$-14,660,000$-16,289,000$-18,443,000$-60,739,000$-47,247,000$-43,496,000$-73,654,000$-39,440,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-44,393,000$-41,400,000$-11,070,000$-10,470,000$-14,660,000$-16,289,000$-18,443,000$-60,739,000$-47,247,000$-43,496,000$-73,654,000$-39,440,000
    EBITDA$-43,754,000$-40,887,000$-10,635,000$-10,039,000$-14,157,000$-15,551,000$-16,927,000$-60,180,000$-46,733,000$-42,972,000$-68,004,000$-40,624,000
    EBIT$-44,393,000$-41,400,000$-11,070,000$-10,470,000$-14,660,000$-16,289,000$-18,443,000$-60,739,000$-47,247,000$-43,496,000$-73,654,000$-39,440,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IVVD

    News

    Invivyd starts FLINTLOCK study: what it means for Invivyd stock

    Invivyd has initiated the FLINTLOCK Phase 2 study for VYD2311 to treat Long COVID and Post-Vaccination Syndrome...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Invivyd launches phase 2 trial of VYD2311 for long COVID By Investing.com

    Invivyd, Inc. (NASDAQ:IVVD) has initiated a Phase 2 clinical trial named FLINTLOCK to evaluate its monoclonal antibody VYD2311 for adults suffering from Long COVID or Post-Vaccination Syndrome. The trial will involve...

    Investing.com India•10/14/26•Somewhat-Bullish

    Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

    Invivyd, Inc. and the SPEAR Study Group have initiated the "FLINTLOCK" Phase 2 clinical trial for VYD2311, a high-dose monoclonal antibody...

    Carroll County Mirror-Democrat•10/14/26•Bullish

    Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

    Invivyd, Inc. and the SPEAR Study Group have announced the initiation of the "FLINTLOCK" Phase 2 clinical trial for VYD2311, a high-dose monoclonal antibody. This study will evaluate the safety, tolerability...

    Yahoo Finance Singapore•10/14/26•Bullish

    Invivyd grants 157,500 options: what it means for Invivyd stock

    Invivyd, Inc. granted 157,500 stock options to six new employees on October 1, 2026, with an exercise price of USD 0.82. The company's market capitalization was USD 190.3 million as of October 13...

    ad-hoc-news.de•10/14/26•Neutral

    IVVD Valuation and Fair Value

    P/E
    -1.8x
    Forward P/E
    44.6x
    P/B
    1.2x
    See GNG's fair value

    IVVD Profitability: Margins, ROIC and FCF

    Gross margin
    92.2%
    Operating margin
    -320.8%
    Net margin
    -183.9%
    ROE
    -95.9%
    FCF margin
    -187.9%

    IVVD Competitors

    CompanyTicker
    Sionna Therapeutics, Inc. Common StockSION
    Sutro BiopharmaSTRO
    Sharps Technology IncSTSS
    Oramed Pharmaceuticals IncORMP
    Upstream Bio, Inc.UPB
    Whitehawk Therapeutics, Inc.WHWK
    Rxsight IncRXST
    Precision BioSciences IncDTIL

    Sector: Healthcare

    IVVD Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IVVD Bull Case vs Bear Case

    Bull case

    • IVVD grew quarterly revenue 21.2% year over year.

    Bear case

    • IVVD has a -183.9% net profit margin.
    • IVVD beat EPS estimates in 37.5% of its last 8 reported quarters.

    IVVD Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -201.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.15
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About IVVD

    Does IVVD pay dividends?

    Invivyd Inc. (IVVD) does not currently pay a regular dividend.

    What is IVVD's market cap?

    Invivyd Inc. (IVVD) has a market capitalization of $179.15M with a current stock price of $0.67.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In